MedTrace Logo

Henan STEMI Registry

NCT02641262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5479

Last updated 2022-08-05

No results posted yet for this study

Summary

ST-segment elevation myocardial infarction (STEMI) remains among the most acute and critical diseases, with primary percutaneous coronary intervention (pPCI) and thrombolysis as mainstay reperfusion treatments. Real-world implementation of current guidelines for STEMI management has been assessed in developed countries and large Chinese cities. However, until now, there has been no registry on patients with STEMI in Henan, the most populated (about 100 million) and predominantly rural (66%) province in central China.

This registry is aimed to assess management practices, time delays, outcomes and reasons for not receiving reperfusion therapy in consecutive STEMI patients in reperfusion-capable hospitals, i.e., tertiary and secondary, in Henan province.

Conditions

  • ST-segment Elevation Myocardial Infarction

Sponsors & Collaborators

  • Henan Institute of Cardiovascular Epidemiology

    lead OTHER

Principal Investigators

  • Chuanyu Gao, MD · Henan Institute of Cardiovascular Epidemiology

  • Dayi Hu, MD · Henan Institute of Cardiovascular Epidemiology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-08-31
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02641262 on ClinicalTrials.gov